Literature DB >> 21698649

CINRG pilot trial of coenzyme Q10 in steroid-treated Duchenne muscular dystrophy.

Christopher F Spurney1, Carolina Tesi Rocha, Erik Henricson, Julaine Florence, Jill Mayhew, Ksenija Gorni, Livia Pasquali, Alan Pestronk, Gerard R Martin, Fengming Hu, Lei Nie, Anne M Connolly, Diana M Escolar.   

Abstract

INTRODUCTION: Corticosteroid treatment slows disease progression and is the standard of care for Duchenne muscular dystrophy (DMD). Coenzyme Q10 (CoQ10) is a potent antioxidant that may improve function in dystrophin-deficient muscle.
METHODS: We performed an open-label, "add-on" pilot study of CoQ10 in thirteen 5-10-year-old DMD patients on steroids. The primary outcome measure was the total quantitative muscle testing (QMT) score.
RESULTS: Twelve of 16 children (mean age 8.03 ± 1.64 years) completed the trial. Target serum levels of CoQ10 (≥2.5 μg/ml) were shown to be subject- and administration-dependent. Nine of 12 subjects showed an increase in total QMT score. Overall, CoQ10 treatment resulted in an 8.5% increase in muscle strength (P = 0.03).
CONCLUSIONS: Addition of CoQ10 to prednisone therapy in DMD patients resulted in an increase in muscle strength. These results warrant a larger, controlled trial of CoQ10 in DMD.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21698649      PMCID: PMC3136634          DOI: 10.1002/mus.22047

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  21 in total

1.  Clinical evaluator reliability for quantitative and manual muscle testing measures of strength in children.

Authors:  D M Escolar; E K Henricson; J Mayhew; J Florence; R Leshner; K M Patel; P R Clemens
Journal:  Muscle Nerve       Date:  2001-06       Impact factor: 3.217

2.  Pre-clinical screening of drugs using the mdx mouse.

Authors:  J A Granchelli; C Pollina; M S Hudecki
Journal:  Neuromuscul Disord       Date:  2000-06       Impact factor: 4.296

3.  Coenzyme Q10: absorption, antioxidative properties, determinants, and plasma levels.

Authors:  Jari Kaikkonen; Tomi-Pekka Tuomainen; Kristiina Nyyssonen; Jukka T Salonen
Journal:  Free Radic Res       Date:  2002-04

4.  Coenzyme q10 prevents apoptosis by inhibiting mitochondrial depolarization independently of its free radical scavenging property.

Authors:  Laura Papucci; Nicola Schiavone; Ewa Witort; Martino Donnini; Andrea Lapucci; Alessio Tempestini; Lucia Formigli; Sandra Zecchi-Orlandini; Giovanni Orlandini; Giuseppe Carella; Rosario Brancato; Sergio Capaccioli
Journal:  J Biol Chem       Date:  2003-05-07       Impact factor: 5.157

5.  The use of score tests for inference on variance components.

Authors:  Geert Verbeke; Geert Molenberghs
Journal:  Biometrics       Date:  2003-06       Impact factor: 2.571

Review 6.  Assay of coenzyme Q10 in plasma by a single dilution step.

Authors:  Gian Paolo Littarru; Fabrizio Mosca; Daniele Fattorini; Stefano Bompadre; Maurizio Battino
Journal:  Methods Enzymol       Date:  2004       Impact factor: 1.600

7.  Clinical investigation of Duchenne muscular dystrophy. A methodology for therapeutic trials based on natural history controls.

Authors:  J R Mendell; M A Province; R T Moxley; R C Griggs; M H Brooke; G M Fenichel; J P Miller; K K Kaiser; W King; J Robison
Journal:  Arch Neurol       Date:  1987-08

8.  Effective and safe therapy with coenzyme Q10 for cardiomyopathy.

Authors:  P H Langsjoen; K Folkers; K Lyson; K Muratsu; T Lyson; P Langsjoen
Journal:  Klin Wochenschr       Date:  1988-07-01

9.  CINRG pilot trial of oxatomide in steroid-naïve Duchenne muscular dystrophy.

Authors:  Gunnar M Buyse; Nathalie Goemans; Erik Henricson; Alejandro Jara; Marleen van den Hauwe; Robert Leshner; Julaine M Florence; Jill E Mayhew; Diana M Escolar
Journal:  Eur J Paediatr Neurol       Date:  2007-04-24       Impact factor: 3.140

10.  Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10.

Authors:  K Folkers; J Wolaniuk; R Simonsen; M Morishita; S Vadhanavikit
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

View more
  18 in total

Review 1.  What can Duchenne Connect teach us about treating Duchenne muscular dystrophy?

Authors:  Richard T Wang; Stanley F Nelson
Journal:  Curr Opin Neurol       Date:  2015-10       Impact factor: 5.710

Review 2.  What has the mdx mouse model of Duchenne muscular dystrophy contributed to our understanding of this disease?

Authors:  Jennifer Manning; Dervla O'Malley
Journal:  J Muscle Res Cell Motil       Date:  2015-02-11       Impact factor: 2.698

Review 3.  ROS and RNS signaling in skeletal muscle: critical signals and therapeutic targets.

Authors:  Luke P Michaelson; Colleen Iler; Christopher W Ward
Journal:  Annu Rev Nurs Res       Date:  2013

4.  Development of a proxy-reported scale to assess motor function in infants and young children with early-onset neuromuscular disorders.

Authors:  Carlos Capella-Peris; Magalie Emile-Backer; Monique O Shelton; Irene C Chrismer; Mary M Cosgrove; Roxanna M Bendixen; Katherine G Meilleur
Journal:  J Adv Nurs       Date:  2020-12-03       Impact factor: 3.057

Review 5.  The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

Authors:  Robin Lachmann; Benedikt Schoser
Journal:  Orphanet J Rare Dis       Date:  2013-10-12       Impact factor: 4.123

6.  Improvement of endurance of DMD animal model using natural polyphenols.

Authors:  Clementina Sitzia; Andrea Farini; Federica Colleoni; Francesco Fortunato; Paola Razini; Silvia Erratico; Alessandro Tavelli; Francesco Fabrizi; Marzia Belicchi; Mirella Meregalli; Giacomo Comi; Yvan Torrente
Journal:  Biomed Res Int       Date:  2015-03-15       Impact factor: 3.411

7.  Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy.

Authors:  Janelle M Spinazzola; Louis M Kunkel
Journal:  Expert Opin Orphan Drugs       Date:  2016-10-18       Impact factor: 0.694

8.  Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network.

Authors:  Anne M Connolly; Julaine M Florence; Mary M Cradock; Elizabeth C Malkus; Jeanine R Schierbecker; Catherine A Siener; Charlie O Wulf; Pallavi Anand; Paul T Golumbek; Craig M Zaidman; J Philip Miller; Linda P Lowes; Lindsay N Alfano; Laurence Viollet-Callendret; Kevin M Flanigan; Jerry R Mendell; Craig M McDonald; Erica Goude; Linda Johnson; Alina Nicorici; Peter I Karachunski; John W Day; Joline C Dalton; Janey M Farber; Karen K Buser; Basil T Darras; Peter B Kang; Susan O Riley; Elizabeth Shriber; Rebecca Parad; Kate Bushby; Michelle Eagle
Journal:  Neuromuscul Disord       Date:  2013-05-28       Impact factor: 4.296

9.  A video game based hand grip system for measuring muscle force in children.

Authors:  Mark Gotthelf; DeWayne Townsend; William Durfee
Journal:  J Neuroeng Rehabil       Date:  2021-07-10       Impact factor: 4.262

10.  Catalpol counteracts the pathology in a mouse model of Duchenne muscular dystrophy by inhibiting the TGF-β1/TAK1 signaling pathway.

Authors:  Deng-Qiu Xu; Lei Zhao; Si-Jia Li; Xiao-Fei Huang; Chun-Jie Li; Li-Xin Sun; Xi-Hua Li; Lu-Yong Zhang; Zhen-Zhou Jiang
Journal:  Acta Pharmacol Sin       Date:  2020-09-16       Impact factor: 7.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.